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Introduction
Gemtuzumab ozogamicin (GO) was the first antibody directed chemotherapy in
cancer, but has had a chequered development in acute myeloid leukemia (AML)
where it has had clinical exposure in a number of settings. None of the five random-
ized trials in adults (involving 3325 patients) or the trial in children (n=1022)1-6 has
shown that GO improves the rate of remission. In all but one there was no excess
in induction mortality, and even in the trial where this was seen, the explanation
was not that the mortality in the combination arm was high, but that mortality in
Arecent source data meta-analysis of randomized trials in adultsassessing the immunoconjugate gemtuzumab ozogamicin com-bined with standard chemotherapy in acute myeloid leukemia
showed a significant survival benefit in patients without an adverse
karyotype. It is not clear whether the optimal dose should be 3 mg/m2
or 6 mg/m2. In this study, we randomized 788 patients to a single dose
of gemtuzumab ozogamicin 3 mg/m2 or 6 mg/m2 with the first course of
induction therapy. We found that the rate of complete remission was
higher with 3 mg/m2 [82% vs. 76%; odds ratio 1.46 (1.04-2.06); P=0.03],
but this was balanced by a higher rate of complete remission with
incomplete peripheral blood count recovery in the 6 mg/m2 treatment
(10% vs. 7%) resulting in similar overall response rate [89% vs. 86%;
hazard ratio 1.34 (0.88-2.04); P=0.17]. There was no overall difference in
relapse or survival at four years between the arms: 46% vs. 54%; hazard
ratio 1.17 (0.94-1.45), P=0.5, and 50% versus 47%; hazard ratio 1.10
(0.90-1.34), P=0.3, respectively. The 30- and 60-day mortality was signif-
icantly higher in the 6 mg/m2 recipients: 7% versus 3%; hazard ratio 2.07
(1.11-3.87), P=0.02, and 9% versus 5%; hazard ratio 1.99 (1.17-3.39),
P=0.01, respectively, which in addition was associated with a higher rate
of veno-occlusive disease (5.6% vs. 0.5%; P<0.0001). Our conclusion
from this trial is that there is no advantage in using a single dose of 6
mg/m2 of gemtuzumab ozogamicin in combination with induction
chemotherapy when compared with a 3 mg/m2 dose, with respect to
response, disease-free and overall survival, either overall, or in any dis-
ease subgroup. (AML17 was registered as ISRCTN55675535.) 
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ABSTRACT
the control arm was unusually low.3  Five of the six trials
showed a significant reduction in relapse risk. No trial
showed a benefit for patients with adverse cytogenetics.
An up-dated individual patient data-based meta-analysis
of the adult patients confirmed that there was an overall
survival benefit due to the reduction in relapse risk.7
Similar data have since emerged in children.6 In these tri-
als, the dose and schedule of GO differed, being 6 mg/m2
on day 4 in two trials,3,5 3 mg/m2 on day 1 in two trials,1,4
and a fractionated schedule of 3 mg/m2 (to a maximum
dose of 5 mg per dose) on days 1, 4 and 7.2 The latter
schedule was derived from an encouraging study in
relapsed disease.8 The meta-analysis further suggested
that a single dose of 3 mg/m2 was as effective at prevent-
ing relapse as a 6 mg/m2 dose, while having less toxicity,
and, therefore, may be the optimal dose, with the ques-
tion of dose frequency remaining to be confirmed.
The majority of patients in these studies received 3
mg/m2 as a single dose which was given on day 1 of
course 1. This was based on a pilot study which suggested
that toxicity was minimal and efficacy was encouraging at
this dose,9 in contrast to the experience of combining the
licensed dose of 9 mg/m2 with chemotherapy.10 This
assumption turned out to be the case in our large multi-
center setting trial.1 Since the toxicity found in the 3 mg/m2
single dose experience was modest, we postulated that
there was a rationale to compare the higher dose (6
mg/m2) with the 3 mg/m2 dose in the hope that efficacy
could be increased, particularly in patients with adverse
risk cytogenetics. Therefore, as part of the UK NCRI
AML17 trial, we prospectively compared two doses of
GO, 3 mg/m2 versus 6 mg/m2, to be given on day 1 of the
first course of induction treatment.
Methods
The NCRI AML17 trial (ISRCTN55675535) was open to
patients (the majority under 60 years of age, and also including
children) who had any form of de novo or secondary AML and
high-risk MDS (defined as marrow blasts >10%). Acute promye-
locytic leukemia was excluded. As induction treatment, 759 adult
patients were randomized between DA (3+10) (n=380) or ADE
(10+3+5) (n=379) (Figures 1 and 2); 29 children (patients <16 years)
received only ADE. GO was administered on day 1 of the induc-
tion chemotherapy except when the white blood cell (WBC)
count  was more than 30x109/L when cyto-reduction treatment
with hydroxyurea could be given to reduce the count to less than
30x109/L, or the GO delayed until day 4 of chemotherapy. Liver
function biochemistry was required to be less than 2 x ULN (upper
limit of normal). Toxicity was defined as in NCI CTCAE v.3.0.
Veno-occlusive disease (VOD) of the liver was defined by pub-
lished criteria.11 After the first induction course, patients with a
FLT-3 mutation were eligible to enter a randomization to receive
the experimental FLT3 inhibitor lestaurtinib or placebo in a 2:1
ratio after each course of chemotherapy. For other patients who
completed the first induction course, a previously reported validat-
ed score was used to assess the risk of relapse.12 Factors used were
age, presenting WBC count, secondary disease, cytogenetics and
the morphological response of the bone marrow (% blasts) after
the first course. Patients with good or standard risk disease
received the second daunorubicin/cytosine arabinoside course
(with or without etoposide), and were then randomized to receive
either one or two courses of high-dose cytosine arabinoside or
MACE/MidAC as consolidation (Figure 1). High-risk patients
were allocated to a randomization between FLAG-Ida (fludara-
bine/ara-C/G-CSF/idarubicin) or daunorubicin/clofarabine for up
to three courses with the intention to undergo allogeneic trans-
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Table 1. Patients’ characteristics.
Characteristic GO 6 mg/m2 GO 3 mg/m2
(n=395) (n=393)
Chemotherapy
ADE 205 203
DA 190 190
Age
0-15 15 14
16-29 50 51
30-39 40 41
40-49 86 86
50-59 149 148
60+ 55 53
Median 50 50
Range 0-81 0-81
Sex
Female 190 178
Male 205 215
Diagnosis
De novo 336 337
Secondary 37 36
MDS 22 20
WHO PS
0 279 280
1 91 91
2 11 8
3 4 4
4 0 1
Not reported* 10 9
WBC
0-9.9 215 196
10-49.9 126 126
50-99.9 25 39
100+ 29 32
Median 8.8 10.0
Range 0.4-386.5 0.5-291.8
Cytogenetics
Favorable 44 52
Intermediate 272 249
Adverse 60 73
Unknown 19 19
FLT3 ITD
WT 304 321
Mutant 77 57
Unknown 14 15
NPM1c
WT 267 271
Mutant 107 102
Unknown 21 20
ITD/NPM1c
ITD WT, NPM1c WT 233 244
ITD WT, NPM1c Mutant 66 73
ITD Mutant, NPM1c WT 34 27
ITD Mutant, NPM1c Mutant 41 29
Unknown 21 20
Post course 1 risk score
Good risk 62 77
Standard risk 180 165
Poor risk 115 132
Not assessable** 38 19
*Children under the age of 10 completed the WHO play performance score. **Post
course 1 validated risk score12 is not available for patients who suffer induction death,
have missing cytogenetics or in whom a response to course 1 is not available.
plantation. Patients who were not good risk, not FLT3 positive or
adverse risk progressed with the core chemotherapy, but could be
randomized or not to the mTOR inhibitor, everolimus, which was
given between chemotherapy courses. The results of these ran-
domizations will be reported elsewhere, but are taken into
account when assessing the GO dose question in this trial.
Diagnosis was confirmed locally and immunophenotyping and
cytogenetics (20 metaphases) were performed in regional accred-
ited laboratories and classified as previously published.13
Molecular characterization was undertaken in two reference labs.
Supportive care was determined by the policy of each center. Stem
cell transplantation was undertaken in regional transplant centers. 
The trial was sponsored by Cardiff University and approved by
Wales Research Ethics Committee 3 on behalf of all UK investiga-
tors, by the Danish Medicines Agency for sites in Denmark, and by
MEDSAFE for sites in New Zealand. The trial was conducted in
accordance with the Declaration of Helsinki, and received research
funding from Cancer Research UK. GO was provided by Pfizer Inc.
who had no role in the design or management of the trial.
Statistical analysis
Response end point definitions are as described by Cheson.14 All
analyses are by intention-to-treat. Categorical end points [e.g.
complete remission (CR) rates] were compared using Mantel-
Haenszel tests, to give Peto odds ratios and confidence intervals.
Continuous/scale variables were analyzed by non-parametric
(Wilcoxon rank sum) tests. Time-to-event outcomes were ana-
lyzed using the log rank test, with Kaplan-Meier survival curves.
Odds/hazard ratios (OR/HR) less than 1 indicate benefit for the
investigational therapy GO 6 mg/m2 versus GO 3 mg/m2. All sur-
vival percentages are at four years unless otherwise stated.
In addition to overall analyses, exploratory analyses were per-
formed stratified by the randomization stratification parameters
and other important variables, with suitable tests for interaction.
Because of the well-known dangers of subgroup analysis, these
were interpreted with caution. 
The randomization was originally planned to run over the
course of the entire AML17 trial (5 years recruitment); however,
the supply of GO enabled 788 patients to be randomized. This
gave 80% power to detect a 10% absolute improvement in sur-
vival at five years from 45% to 55%, requiring 382 events.
Follow up is complete as at 1st March 2015, with a median fol-
low up for survival of 50 months (range 26.8-67.8 months) and 386
events.
Results
Between June 2009 and October 2011 788 patients were
randomized: their median age was 50 years (range 0-81
years, with 29 aged <16 years). Eighty-five percent had 
de novo AML, 9% secondary AML and 5% high-risk MDS;
53% were male. Thirteen percent were favorable, 69%
intermediate, and 18% adverse cytogenetic risk; the medi-
an presenting WBC was 9.2 (0.4-386.5); 18% had a FLT3
ITD and 28% had an NPM1c mutation (Table 1). Four
hundred and eight patients received ADE (including all 29
children recruited who were allocated ADE therapy) and
380 received DA (Figure 2) as induction treatment.
Remission induction
Eighty-seven percent of all patients entered CR/CRi
(79% CR, 8% complete remission with incomplete blood
count (CRi)]. CR rates were higher in the GO 3 mg/m2 arm
[82% vs. 76%, OR 1.46 (1.04-2.06); P=0.03], but this was
balanced by more CRi with 6 mg/m2 (7% vs. 10%), lead-
ing to no significant difference in overall response rate
(ORR) [9% vs. 86%; OR 1.34 (0.88-2.04); P=0.17] (Table 2).
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Figure 1. Trial design of AML17. ADE: course 1, daunorubicin 50 mg/m2 d 1,3,5; ara-C 100 mg/m2 every 12 hours d 1-10, etoposide 100 mg/m2
d1-5; course 2, daunorubicin 50 mg/m2 d 1,3,5; ara-C 100 mg/m2 every 12 hours d 1-8, etoposide 100 mg/m2 d1-5; DA (no children): course 1
daunorubicin 50 mg/m2 d 1,3,5; ara-C 100 mg/m2 every 12 hours d 1-10, course 2 daunorubicin 50 mg/m2 d 1,3,5; ara-C 100 mg/m2 every 12
hours d 1-8; GO3: gemtuzumab ozogamicin 3 mg/m2 given on day 1 of course 1 of chemotherapy; GO6: gemtuzumab ozogamicin 6 mg/m2 given
on day 1 of course 1 of chemotherapy; Lestaurtinib: lestaurtinib (CEP-701) 40-80 mg bd (depending on azole antifungals) from 2 days post
chemo to 2 days pre subsequent course, up to a maximum of 28 days; mTOR (everolimus, available post October 2009): everolimus 5-10
mg/day, from 2 days post chemo to 2 days pre subsequent course, up to a maximum of 28 days; D Clofarabine (available post November 2009):
daunorubicin 50 mg/m2 d 1,3,5; clofarabine 20 mg/m2 d 1-5; FLAG-Ida: fludarabine 30 mg/m2 (d 2-6); ara-C 2 g/m2 (4 h post fludarabine), d 2-
6; G-CSF 263 g s.c. d 1-7; ara-C (post July 2010): ara-C 3 g/m2 12-hourly, d 1, 3, 5. Patients allocated either CEP-701 or everolimus post course
1 carried this allocation forward into subsequent courses. * Prior to July 2010 patients in the 3 versus 4 course randomization were randomized
between MACE (amsacrine 100 mg/m2 d 1-5, ara-C 200 mg/m2 d 1-5, etoposide 100mg/m2 d 1-5)  and MACE/MidAC (course 3 as above, MidAC:
mitoxantrone 10 mg/m2 d1-5; ara-C 1 g/m2 twice daily d 1-3).
There was no significant difference in remission rates
achieved with the first induction course between the
arms.
Toxicity and supportive care
The 30-day mortality [3% vs. 7%; OR 2.07 (1.11-3.87);
P=0.02] and 60-day mortality [5% vs. 9%; OR 1.99 (1.17-
3.39); P=0.01] were both significantly increased in the 6
mg/m2 arm (Table 2). There were 18 versus 36 deaths with-
in 60 days: the causes of which were infection (10 vs. 11);
infection+hemorrhage (0 vs. 1); hemorrhage (3 vs. 4);
resistant disease (2 vs. 6); veno-occlusive disease (0 vs. 5);
cardiac (1 vs. 3); pulmonary (2 vs. 1); renal (0 vs. 3); or mul-
tiple causes (0 vs. 2). Survival beyond 60 days was the
same in both arms [53% vs. 52%, HR 1.00 (0.81-1.24);
P=1.0]. When grade 3 or 4 toxicities were compared
GO + induction chemotherapy in AML
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Table 2. Trial outcomes and results of dose comparisons.
GO 6 mg/m2 GO 3 mg/m2 OR/HR & CI P
CR 76% 82% 1.46 (1.04-2.06) 0.03
CRi 10% 7%
CR/CRi 86% 89% 1.34 (0.88-2.04) 0.17
Induction death 7% 3%
Resistant disease 7% 8%
CR/CRi post course 1 73% 78% 1.29 (0.93-1.78) 0.13
30-day mortality 7% 3% 2.07 (1.11-3.87) 0.02
60-day mortality 9% 5% 1.99 (1.17-3.39) 0.01
4 year OS 47% 50% 1.10 (0.90-1.34) 0.3
4 year RFS 38% 44% 1.11 (0.91-1.35) 0.3
4 year cumulative incidence of relapse 54% 46% 1.17 (0.94-1.45) 0.15
4 year cumulative incidence of death in CR 9% 10% 0.83 (0.51-1.36) 0.5
4 year OS from CR 53% 56% 1.07 (0.85-1.35) 0.6
4 year OS censored at SCT 53% 60% 1.20 (0.93-1.54) 0.16
OR: odds ratio; HR: hazard ratio; CI: confidence interval; CR: complete remission; CRi: complete remission with incomplete blood count; OS: overall survival; RFS: relapse-free 
survival; SCT: stem cell transplantation.
Figure 2. CONSORT diagram.
between the 3 mg/m2 and 6 mg/m2 doses, alanine transam-
inase (ALT), creatinine and hematuria in course 1 (7% vs.
17%; 1% vs. 2%; 1% vs. 2%, respectively) were the only
significant differences during courses 1 and 2 (Figure 3).
Although the kinetics of peripheral blood recovery were
similar, with the exception of slower platelet recovery,
there was increased platelet transfusion requirement and
increased days on antibiotics during course 1 in the 6
mg/m2 arm, but there were no differences after course 2
(Online Supplementary Table S1).  Central assessment of
VOD was confirmed as definite (n=17) or possible (n=5) in
22 of 395 (5.6%) patients on 6 mg/m2 compared with 2
definite and 0 possible in 2 of 393 on the 3 mg/m2 arm
(0.5%) (P<0.0001).
A. Burnett et al.
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Figure 3. Grade 3-4 toxicities following (A) course 1, (B) course 2.
Figure 4. Outcomes for gemtuzumab ozogamicin dose randomization: (A) cumulative incidence of relapse; (B) cumulative incidence of death in
remission; (C) relapse-free survival; (D) overall survival.
A B
A B
C D
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Figure 5. Stratified analysis of survival.
Relapse and survival
There was no significant difference in relapse [46% vs.
54%, HR 1.17 (0.94-1.45), P=0.15] or death in remission
[(10% vs. 9%, HR 0.83 (0.51-1.36) P=0.5)] leading to no
significant differences in relapse-free survival which was
41% overall [44% vs. 38%; HR 1.11 (0.91-1.35); P=0.3]
(Table 2 and Figure 4). Four-year overall survival was 49%
[50% vs. 47%; HR 1.10 (0.90-1.34); P=0.3] (Table 2 and
Figure 4D). There was no difference in mortality after day
60. A total of 329 patients received transplant; of the 273
allografts, 158 were performed in first remission. The dis-
tribution of transplants was similar between the arms, and
censoring survival at stem cell transplant did not alter the
overall treatment effect. Neither the 3 mg/m2 or the 6
mg/m2 dose caused excessive post-transplant toxicity;  in
particular no liver toxicity was observed. 
Exploration of subgroups
No subgroup showed any suggestion of a significant
response or survival benefit from the 6 mg/m2 dose, but
there was a   trend for  benefit for both response rate (test
for heterogeneity P=0.02) (Online Supplementary Figure S1)
and overall survival (test for heterogeneity P=0.04) (Figure
5) in the adverse cytogenetics patients (n=133).
Discussion
In the early studies of GO, it was observed that there
was an association with the then licensed dose (9 mg/m2)
and liver toxicity if combined with chemotherapy or stem
cell transplant.15 The risk was related to the time interval to
or from transplant.16 The pathological diagnosis was
referred to as sinusoidal obstructive syndrome (SOS) and
thought likely to be caused by cytotoxicity to leukemia
cells which had accumulated in the liver sinusoids.11
However, the concept of augmenting treatment with tar-
geted chemotherapy remained attractive, but establishing
the dose which could safely be combined with standard
intensive chemotherapy required a dose-finding trial. To
do this, we tested the DAT chemotherapy schedule
(daunorubicin, Ara-C, thioguanine). It emerged that the
observed liver toxicity was associated with the use of
thioguanine, which, somewhat fortunately, became
unavailable.9 Since the efficacy in that pilot study was
encouraging at the 3 mg/m2 dose, this was adopted as the
study dose for the subsequent large trials conducted by
our group.
Since minimal toxicity was seen, the question remained
as to whether we were under-dosing at this level, even
although the dose was effective in patients who did not
have adverse risk disease. Subsequently a 6 mg/m2 was
adopted by others,3,5 so we thought it relevant to examine
this dose to better define the dose level required. In this
large randomized study we saw no significant benefit of
using GO at the 6 mg/m2 dose, although there was a pos-
sible trend for benefit in the adverse risk patients who
have not been shown to benefit from GO irrespective of
dose or schedule in other trials. The 6 mg/m2 dose did
have a detrimental effect with respect to liver toxicity and
platelet count recovery, and significantly increased the day
30 and 60 mortality; this suggests that in cases in which a
single dose schedule is used, the 3 mg/m2 dose is adequate.
The remaining issue is whether a single dose is inferior
to the fractionated dosing schedule developed by the
French group. The rationale for this approach is that, fol-
lowing exposure to antibody, there is re-expression of
CD33 within hours, and, therefore, it is logical to expect a
repeated challenge.17 This was endorsed by the initial
study in relapsed disease8 where 57 patients were treated
with the 1-, 4- and 7-day schedule and achieved an overall
response rate of 33% [26% CR and 7% complete remis-
sion with incomplete platelet recovery (CRp)] with mini-
mal toxicity.
The French ALFA group took this forward to front-line
treatment in a randomized study involving 280 non-favor-
able risk patients who were randomized to receive the
addition of GO in a dose of 3 mg/m2 in a day 1, 4 and 7
schedule with the first induction course, followed by  a
single dose each of two post induction courses. This pro-
duced a very encouraging initial report with a significant
survival benefit,2 but one that longer follow up has shown
to be a little less clear.18 However, in that study, each dose
was capped at 5 mg and the schedule given was on day 1,
4 and 7, and also as a single dose  in consolidation. It is
plausible that at least some of the benefit was due to dos-
ing in consolidation. There was some hematologic toxici-
ty, particularly to platelets. So while a 3 mg/m2 dose
appears adequate, an optimal schedule still has to be
defined. However, the MRC AML15 trial did not show
any additional benefit of adding GO to consolidation irre-
spective of whether it had been given with the first induc-
tion course,1 so the pressing issue to be resolved is
whether the single or fractionated schedule is to become
the standard approach. To resolve this, we have initiated a
direct comparison of a 3 mg/m2 dose on day 1 versus days
1 and 4 in our ongoing trials (registered as
ISRCTN31682779 and ISRCTN78449203).
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